Clinical Trials

The Tumor Immunotherapy Program has a number of studies that are currently recruiting patients. For information about how to be referred to one of these studies, please contact us.

Closed Recruiting

  • Sitravatinib (MGCD516) and Nivolumab in Oral cavity cancer Window opportunity study (SNOW)
    Eligible Tumour Type(s): Squamous Cell Carcinoma of the Oral Cavity
    Sponsor: In-house
    Principal Investigator: Lillian Siu
    NCT#: NCT03575598
  • TILs-001-DC

    A Phase I Study evaluating the feasibility and safety of infusion of Re-StimulatedAutologous tumor-infiltrating lymphocytes (TILs) followed by low-dose interleukin-2 therapy in patients with platinum resistant high grade serous ovarian, fallopian tube, or primary peritoneal cancer

    Eligible Tumour Type(s): Ovarian Cancer
    Sponsor: In-House
    Principal Investigator: Marcus Butler
    NCT#: NCT01883297

    https://clinicaltrials.gov/ct2/show/NCT01883297

  • TILs-002-MEL

    Phase II Study evaluating the infusion of autologous tumor-infiltrating lymphocytes (TILs) and low-dose interleukin-2 (IL-2) therapy following a preparative regimen of non-myeloablative lymphodepletion using cyclophosphamide and fludarabine in patients with metastatic melanoma.

    Eligible Tumour Type(s): Metastatic Melanoma
    Sponsor: In-House
    Principal Investigator: Marcus Butler
    NCT#: NCT01883323

    https://clinicaltrials.gov/ct2/show/NCT01883323?term=TILs-002-MEL&rank=1

  • TILs-003-Meso

    Phase I/II study evaluating the infusion of tumor-infiltrating lymphocytes (TILs) and low-dose interleukin-2 (IL-2) therapy following a preparative regimen of non-myeloablative lymphodepletion using cyclophosphamide and fludarabine in patients with malignant pleural mesothelioma)

    Eligible Tumour Type(s): Malignant Pleural Mesothelioma
    Sponsor: In-House
    Principal Investigator: Marcus Butler
    NCT#: NCT02414945

    https://clinicaltrials.gov/ct2/show/NCT02414945?term=TILs-003-Meso&rank=1

  • INSPIRE

    INvestigator-initiated Phase II Study of pembrolizumab immunological response evaluation

    Eligible Tumour Type(s): Metastatic Melanoma, Ovarian Cancer, Solid Cancer, Squamous Cell Cancer of the Head and Neck, Triple Negative Breast Cancer
    Sponsor: In-House
    Principal Investigator: Lillian Siu
    NCT#: NCT02644369

    https://clinicaltrials.gov/ct2/show/NCT02644369

  • ACTIVATE

    Phase Ib trial of pembrolizumab administered in combination or following adoptive cell therapy: A multiple cohort study

    Eligible Tumour Type(s): Metastatic Melanoma, Ovarian Cancer
    Sponsor: In-House
    Principal Investigator: Marcus Butler
    NCT#: NCT02811497

    https://clinicaltrials.gov/ct2/show/NCT03158935

  • METADUR

    An open-label, phase II basket study of a hypomethylating agent azacitidine and durvalumab (anti-PDL1) in advanced solid tumors.

    Eligible Tumour Type(s): Breast Cancer, Colorectal Cancer, Ovarian Cancer
    Sponsor: In-House
    Principal Investigator: Lillian Siu
    NCT#: NCT02811497

    https://clinicaltrials.gov/ct2/show/NCT02811497

Pages